author-photo

Tianxiang Lin

Washington University in St. Louis

11

Papers

173

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

2020 medRxiv
Show All
- Source
- Cite
- Save
Citations (1)
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (44)
Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity

2018 Cell Reports
Show All
- Source
- Cite
- Save
Citations (14)
Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma

2017 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (15)
Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (18)
Abstract 3847: Oral cavity squamous cell carcinoma xenografts display conservation of primary tumor genomic heterogeneity

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (57)
Abstract PR01: Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Abstract CT070: Biomarker and clinical response of oral cavity squamous cell carcinoma to the MEK 1/2 inhibitor trametinib: A phase II neoadjuvant window of opportunity clinical trial

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)